cardiotoxicity/phosphatase

This is a pilot study with a descriptive study design. Anthracycline induced late onset cardiotoxicity, defined in terms of abnormal findings on echocardiography, has been reported to occur in 57% of childhood cancer survivors. Serial monitoring of cardiac function by means of echocardiography

1. Background During the past 30 years, survival of breast cancer patients has improved substantially due to earlier diagnosis, improved surgical techniques, introduction of new combination of chemotherapy, new hormonal treatment, introduction of targeted treatment, and refinement of radiation

1.0 Background While atrial fibrillation (AF) is the most common sustained cardiac arrhythmia requiring therapy, it is also associated with increased risk of stroke, heart failure, myocardial infarction, dementia, and death. The number of Americans affected with AF is expected to surge to nearly 16

Part A: Patients who received a high dose of anthracyclines and who completed chemotherapy for a minimum of 2 year and are still in remission we gathered information about their previous heart disease, radiation dose to the heart, bone marrow transplant, age at treatment, gender, elevation of serum

Prospective, randomized pharmacological intervention study Primary objectives: - to determine whether concurrent ATII-antagonist treatment can prevent trastuzumab-related cardiotoxicity, defined as a decline in LVEF of more than 15% or a decrease to an absolute value <45% Secondary objectives: - To